According to WHO's press statement, after 2 days of discussion on potential Ebola therapies and vaccines, more than 150 participants, representing the fields of research and clinical investigation, ethics, legal, regulatory, financing, and data collection, identified several therapeutic and vaccine interventions that will be the focus of priority clinical evaluation.
The following is the complete press statement from the WHO website:
A number of candidate vaccines and therapies have been developed and tested in animal models and some have demonstrated promising results.
Safety in humans is also unknown, raising the possibility of adverse side effects when administered. Use of some of these products is demanding and requires intravenous administration and infrastructure, such as cold chain, and facilities able to offer a good and safe standard of care.
The experts determined:
• There was consensus that the use of whole blood therapies and convalescent blood serums needs to be considered as a matter of priority.